Clinical Trials/NCT00000232

NCT00000232

Completed

Phase 2

Alternate Day Buprenorphine Administration, Phase IX

University of Vermont1 site in 1 countryMarch 1992

ConditionsOpioid-Related Disorders

DrugsBuprenorphine

Overview

Phase: Phase 2
Intervention: Not specified
Conditions: Opioid-Related Disorders
Sponsor: University of Vermont
Locations: 1
Primary Endpoint: Opioid agonist effects
Status: Completed
Last Updated: 9 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of this study is to determine if four times a subjects' daily maintenance dose will hold for 120 hours without changes in agonist and antagonist effects.

Registry

clinicaltrials.gov

Start Date

March 1992

End Date

TBD

Last Updated

9 years ago

Study Type

Interventional

Study Design

Crossover

Sex

All

Investigators

Sponsor

University of Vermont

Eligibility Criteria

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Outcomes

Primary Outcomes

Opioid agonist effects

Pupil diameter

Dose identification

Drug use

Opioid withdrawal

Study Sites (1)

Loading locations...

Similar Trials

Completed

Phase 2

Alternate-Day Buprenorphine Administration. Phase VII - 8Opioid-Related Disorders

NCT00000226National Institute on Drug Abuse (NIDA)

Completed

Phase 2

Alternate-Day Buprenorphine Administration. Phase VI - 7Opioid-Related Disorders

NCT00000225National Institute on Drug Abuse (NIDA)

Completed

Phase 1

Alternate-Day Buprenorphine Administration. Phase II - 4Opioid-Related Disorders

NCT00000222National Institute on Drug Abuse (NIDA)

Completed

Phase 1

Alternate-Day Buprenorphine Administration. Phase I - 3Opioid-Related Disorders

NCT00000221National Institute on Drug Abuse (NIDA)

Completed

Phase 2

Alternate-Day Buprenorphine Administration. Phase IV - 5Opioid-Related Disorders

NCT00000223National Institute on Drug Abuse (NIDA)